menu
    • menu
    [{"orgOrder":0,"company":"CSIRO","sponsor":"Recce Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Recce 327","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CSIRO","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CSIRO \/ CSIRO","highestDevelopmentStatusID":"4","companyTruncated":"CSIRO \/ CSIRO"},{"orgOrder":0,"company":"CSIRO","sponsor":"Amplia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"AMP945","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"CSIRO","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"CSIRO \/ CSIRO","highestDevelopmentStatusID":"4","companyTruncated":"CSIRO \/ CSIRO"}]

    Find Clinical Drug Pipeline Developments & Deals by CSIRO

    Menu

    CSIRO

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CSIRO

                            Australia arrow
                            BioFlorida Conference
                            Not Confirmed

                            CSIRO

                            Australia arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMP945

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Recipient : Amplia Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Amplia Receives Grant to Collaborate with CSIRO – Supplementary Announcement

                            Details : The research collaboration with CSIRO will help to develop formulations of its small molecule FAK inhibitors, including AMP945 that could be applied topically to wounds and burns to aid healing and reduce scarring.

                            Brand Name : AMP945

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 23, 2023

                            Lead Product(s) : AMP945

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Recipient : Amplia Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CSIRO

                            Australia arrow
                            BioFlorida Conference
                            Not Confirmed

                            CSIRO

                            Australia arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recce 327

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Recce Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Recce Pharmaceutical's RECCE® Compounds Selected by CSIRO/Doherty Institute in Priority 1 Candidate Group for...

                            Details : RECCE® 327 and New RECCE® 529 compounds were selected for their unique mechanisms of action against hyper-mutation, as indicated on bacteria and viruses (respectively).

                            Brand Name : Recce 327

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 08, 2020

                            Lead Product(s) : Recce 327

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Recce Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth